These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1323 related items for PubMed ID: 6762612

  • 1. Blood viscosity and thrombosis: clinical considerations.
    Smith BD, La Celle PL.
    Prog Hemost Thromb; 1982; 6():179-201. PubMed ID: 6762612
    [Abstract] [Full Text] [Related]

  • 2. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients.
    Jespersen J.
    Dan Med Bull; 1988 Feb; 35(1):1-33. PubMed ID: 3277796
    [Abstract] [Full Text] [Related]

  • 3. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR.
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [Abstract] [Full Text] [Related]

  • 4. Oral contraceptive risks: a realistic appraisal.
    Bressler R, Durand JL.
    Drug Ther (NY); 1979 Oct; 9(10):81-95. PubMed ID: 12279276
    [Abstract] [Full Text] [Related]

  • 5. [Oral contraception and the vascular risk].
    Garnier LF, Gruel Y.
    Servir; 1989 Oct; 37(6):322-6. PubMed ID: 2517520
    [Abstract] [Full Text] [Related]

  • 6. Oral contraception and coagulation.
    Notelovitz M.
    Clin Obstet Gynecol; 1985 Mar; 28(1):73-83. PubMed ID: 3987135
    [Abstract] [Full Text] [Related]

  • 7. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
    Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Koster T, Bertina RM, Vandenbroucke JP.
    Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
    [Abstract] [Full Text] [Related]

  • 8. [Vascular disease and hormonal treatment--epidemiology].
    Vessey MP.
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):121-6. PubMed ID: 12280197
    [Abstract] [Full Text] [Related]

  • 9. [Cardiovascular risks of oral contraceptives: dose-response relationship].
    Kelleher CC.
    Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY, Plu-Bureau G, Zitoun D, Bara L, Guize L, Samama MM.
    Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
    [Abstract] [Full Text] [Related]

  • 13. Thrombotic disorders associated with pregnancy and the pill.
    Tooke JE, McNicol GP.
    Clin Haematol; 1981 Jun; 10(2):613-30. PubMed ID: 7032788
    [Abstract] [Full Text] [Related]

  • 14. The hypercoagulable states.
    Schafer AI.
    Ann Intern Med; 1985 Jun; 102(6):814-28. PubMed ID: 3158262
    [Abstract] [Full Text] [Related]

  • 15. Current perspectives in the treatment of thrombotic disorders.
    Drouet L, Caen JP.
    Semin Thromb Hemost; 1989 Apr; 15(2):111-22. PubMed ID: 2665082
    [Abstract] [Full Text] [Related]

  • 16. [Oral contraceptives and blood platelets].
    Davenas E, Ciavatti M, Poitevin B, Aubin M.
    Homeopath Fr; 1985 Apr; 73(5):299-305. PubMed ID: 12281246
    [Abstract] [Full Text] [Related]

  • 17. [Prevention of cerebrovascular circulatory disorders].
    Herrschaft H.
    Fortschr Neurol Psychiatr; 1985 Sep; 53(9):337-43. PubMed ID: 4043914
    [Abstract] [Full Text] [Related]

  • 18. The investigation of a heart valve patient with suspected hypercoagulability.
    Gough SC, Prentice CR.
    J Heart Valve Dis; 1993 Jan; 2(1):7-17. PubMed ID: 8269113
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Activated protein C resistance--a major risk factor for thrombosis.
    Rosén SB, Sturk A.
    Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 67.